{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T05:48:49Z","timestamp":1791611329425,"version":"4.3.4"},"reference-count":12,"publisher":"Japanese Urological Association","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2026,7,20]]},"DOI":"10.5980\/jpnjurol.117.74","type":"journal-article","created":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:13:29Z","timestamp":1791497609000},"page":"74-78","source":"Crossref","is-referenced-by-count":0,"title":["A CASE OF CYTOKINE RELEASE SYNDROME FOLLOWING COMBINATION THERAPY WITH IPILIMUMAB AND NIVOLUMAB FOR ADVANCED RENAL CELL CARCINOMA","\u9032\u884c\u6027\u814e\u764c\u306b\u5bfe\u3057\u3066\u30a4\u30d4\u30ea\u30e0\u30de\u30d6\uff0c\u30cb\u30dc\u30eb\u30de\u30d6\u4f75\u7528\u7642\u6cd5\u958b\u59cb\u5f8c\uff0c\u30b5\u30a4\u30c8\u30ab\u30a4\u30f3\u653e\u51fa\u75c7\u5019\u7fa4\u3092\u6765\u3057\u305f1\u4f8b"],"prefix":"10.5980","volume":"117","author":[{"given":"Hironobu","family":"Okugi","sequence":"first","affiliation":[{"name":"Department of Urology, Public Tatebayashi Kosei General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsugufumi","family":"Tsukumo","sequence":"additional","affiliation":[{"name":"Department of Urology, Public Tatebayashi Kosei General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Agata","sequence":"additional","affiliation":[{"name":"Department of Urology, Japanese Red Cross Maebashi Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Okazaki","sequence":"additional","affiliation":[{"name":"Department of Urology, Public Tatebayashi Kosei General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Urology, Public Tatebayashi Kosei General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4001","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Garc\u00eda Roche A, D\u00edaz Lagares C, \u00c9lez E and Ferrer Roca R: Cytokine release syndrome. Reviewing a new entity in the intensive care unit. Med Intensiva (Engl Ed), 43, 480-488, 2019.","DOI":"10.1016\/j.medin.2019.01.009"},{"key":"2","unstructured":"2) \u65e5\u672c\u81e8\u5e8a\u816b\u760d\u5b66\u4f1a\u7de8: \u304c\u3093\u514d\u75ab\u7642\u6cd5\u30ac\u30a4\u30c9\u30e9\u30a4\u30f3. \u7b2c3\u7248, p 96-97, \u91d1\u539f\u51fa\u7248, \u6771\u4eac, 2023."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Inoue T, Todaka A, Fuse M, Suzuki S, Sejiyama S, Ando T and Shin T: Cytokine release syndrome treated with tocilizumab following ipilimumab-nivolumab combination therapy in advanced renal cell carcinoma. IJU Case Rep, 8, 64-68, 2025.","DOI":"10.1002\/iju5.12812"},{"key":"4","doi-asserted-by":"crossref","first-page":"2372875","DOI":"10.1080\/2162402X.2024.2372875","volume":"13","author":"O Hamida","year":"2024","unstructured":"4) Hamida O, Karlsson F, Lundqvist A, Gerling M and Liu LL: Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden. Oncoimmunology, 13, 2372875, 2024.","journal-title":"OncoImmunology","ISSN":"https:\/\/id.crossref.org\/issn\/2162-4011","issn-type":"print"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Yoshimura A, Yamamoto Y, Nishikawa T, Fujita M, Inoue T, Kondo F, Hayashi T, Kawamura N, Nagahara A, Nakai Y, Nakayama M and Nishimura K: Relapsing cytokine release syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab and axitinib therapy. Int Cancer Conf J, 13, 26-32, 2023.","DOI":"10.1007\/s13691-023-00630-w"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Tay SH, Toh MMX, Thian YL, Vellayappan BA, Fairhurst A-M, Chan YH, Aminkeng F, Bharwani LD, Huang Y, Mak A and Wong ASC: Cytokine release syndrome in cancer patients receiving immune checkpoint inhibitors: a case series of 25 patients and review of the literature. Front Immunol, 13, 807050, 2022.","DOI":"10.3389\/fimmu.2022.807050"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Shimabukuro-Vornhagen A, G\u00f6del P, Subklewe M, Stemmler HJ, Schl\u00f6\u00dfer HA, Schlaak M, Kochanek M, B\u00f6ll B and von Bergwelt-Baildon MS: Cytokine release syndrome. J Immunother Cancer, 6, 56, 2018.","DOI":"10.1186\/s40425-018-0343-9"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8) Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA and Mackall CL: Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 124, 188-195, 2014.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Fajgenbaum DC and June CH: Cytokine storm. N Engl J Med, 383, 2255-2273, 2020.","DOI":"10.1056\/NEJMra2026131"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Ohira J, Kawamoto M, Sugino Y and Kohara N: A case report of fulminant cytokine release syndrome complicated by dermatomyositis after the combination therapy with immune checkpoint inhibitors. Medicine (Baltimore), 99, e19741, 2020.","DOI":"10.1097\/MD.0000000000019741"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yamamoto K, Shiotsu S, Sasakura M, Tanaka S, Goda S, Tsuji T, Yuba T, Takumi C and Hiraoka N: Cytokine release syndrome with relative adrenal insufficiency induced by ipilimumab and nivolumab combination therapy for clear cell renal cell carcinoma. Intern Med, 63, 2703-2707, 2024.","DOI":"10.2169\/internalmedicine.3115-23"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Urasaki T, Ono M, Mochizuki T, Takeda K, Nishizawa K, Fukagawa E, Fujiwara M, Komai Y, Kitano S, Yuasa T, Yonese J and Takahashi H: A case of trimethoprim\/sulfamethoxazole-triggered hypotensive shock: cytokine release syndrome related to immune checkpoint inhibitors and drug-induced hypersensitivity syndrome. Front Oncol, 11, 681997, 2021.","DOI":"10.3389\/fonc.2021.681997"}],"container-title":["The Japanese Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/117\/3\/117_74\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:55:28Z","timestamp":1791608128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/117\/3\/117_74\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":12,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.117.74","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]}}}